title: Heterotopic ossification after hip arthroplasty: a randomized double-blind multicenter study tenoxicam in 147 hips.
abstract: 147 patients due to have a cemented total hip arthroplasty were randomized to 4 groups. They received either tenoxicam 20 mg or 40 mg, or placebo, for 5 days or morphine on the day of operation and placebo for 4 days. During the first 5 days 14 patients were excluded. The patients were followed for 1 year, during which another 10 patients were excluded. At follow-up, significantly fewer patients had heterotopic ossifications in the tenoxicam groups than in the placebo and morphine groups. There was no significant difference between the 2 tenoxicam-treated groups, and we therefore conclude that tenoxicam 20 mg for 5 days postoperatively can reduce heterotopic ossification after cemented total hip arthroplasty.
authors.affiliation: Department of Orthopedics, Hvidovre University Hospital, Denmark.
authors.forename: P
authors.initials: P
authors.lastname: Gebuhr
authors.forename: J
authors.initials: J
authors.lastname: Sletgård
authors.forename: J
authors.initials: J
authors.lastname: Dalsgård
authors.forename: M
authors.initials: M
authors.lastname: Soelberg
authors.forename: K
authors.initials: K
authors.lastname: Keisu
authors.forename: A
authors.initials: A
authors.lastname: Hänninen
authors.forename: M
authors.initials: M
authors.lastname: Crawford
mesh_terms: D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000627:therapeutic use*; D004311:Double-Blind Method; D006622:Hip Prosthesis; D006801:Humans; D009999:Ossification, Heterotopic / Q000517:prevention & control*; D010894:Piroxicam / Q000031:analogs & derivatives* / Q000627:therapeutic use; D011183:Postoperative Complications / Q000517:prevention & control*; D016896:Treatment Outcome
chemical_list: D000894:Anti-Inflammatory Agents, Non-Steroidal; D010894:Piroxicam; C032801:tenoxicam